MedRod® dosing technology
Registered Trademark Developed By Preclinapps
MedRod®
Delivers active ingredient in efficient and reliable manner to support and improve the quality of preclinical studies.
It is stable and cost-effective substitute to chronic injections.
MedRod® dosing technology for preclinical animal research
In MedRod® implant the active compounds are dispersed in flexible, polymeric cylindrical rods, optionally covered by membrane or coating. The process results in elastic MedRod® where compound is safely immobilized and steadily released for several months. MedRod® implants are intended for in vitro or in vivo preclinical studies.
MedRod® implants have been validated with several immunodeficient mouse strains, including athymic nude, NOG, NSG, balb/c nude and SCID mice as well as with many hormone-dependent breast and prostate cancer cell lines such as, MCF-7, BT-474 and LNCaP cells.
Safe long-term controlled drug release from a week even to years
Elastic and biocompatible soft matrix. Each batch and dosage validated unlike competing long-term drug delivery systems
Controlled release with known daily doses minimizes the risk of toxic or adverse effects of drug
Suitable for variety of molecule types
Drug substances such as estrogens, androgens, progestins, glucocorticoids and other small molecules (such as 17beta estradiol, DHT, testosterone) have an excellent continuous drug release profile from MedRod® implants
Wide concentration range and target animals
Dose range from 10 ng/day even up to 200 mcg/day. Typically used in ER and AR-dependent xenograft, syngeneic and PDX cancer studies and metabolic studies in mice, but also in rats or even larger animals (dog, minipig)